Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lithium + mirtazapine + venlafaxine
- Development stage
- Preclinical
- Lead developer
- zyvran pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZYN 003 (Z978X) is an oral fixed-dose combination drug candidate being developed by Zyvran Pharmaceuticals for the treatment of treatment-resistant depression (TRD). The composite formulation combines three distinct active ingredients with complementary mechanisms of action: venlafaxine (a serotonin-norepinephrine reuptake inhibitor, or SNRI), mirtazapine (a tetracyclic antidepressant, or TeCA), and lithium (a mood stabilizer). By merging these distinct pharmacological classes, ZYN 003 aims to target multiple neurotransmitter pathways simultaneously, providing enhanced therapeutic efficacy and rapid relief for patients who have failed to respond to standard antidepressant therapies.
- Other names
- ZYN-003ZYN003ZYN 003lithium + mirtazapine + venlafaxinevenlafaxine + mirtazapine + lithium
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)ARRB2 (Beta-arrestin-2)GSK3 (Glycogen synthase kinase 3 beta)IMPA1 (Inositol Monophosphatase)INPP1 (Inositol polyphosphate 1-phosphatase)PP2A (Protein phosphatase 2A)mTOR (Mammalian target of rapamycin kinase)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)HRH1 (Histamine H1 Receptor)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on lithium + mirtazapine + venlafaxine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lithium + mirtazapine + venlafaxine.